News

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

January 26, 2023

REDWOOD CITY, Calif. , Jan. 26, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...

Read More

Soleno Therapeutics Announces Financing Commitment for up to $60 Million

December 19, 2022

Funding from three leading healthcare investors, with Vivo Capital joining existing investors Nantahala Capital and ...

Read More

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 09, 2022

REDWOOD CITY, Calif. , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...

Read More